GlassScriptPhysician profile
Artem Sunik
NPI 1861710592
$5,679.59
in general payments reported to CMS, 2019-2025
31 companies · $965 in 2025
The $965 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $360 · 2021: $642 · 2022: $307 · 2023: $1,538 · 2024: $1,257 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,760.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $667.96 | 2021-2025 | Xcopri |
| Ucb, INC. | $642.81 | 2019-2024 | Briviact |
| Abbvie INC. | $638.39 | 2021-2025 | Qulipta, Ubrelvy |
| Axsome Therapeutics, INC. | $365.65 | 2023-2024 | Auvelity |
| Pfizer INC. | $363.26 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $349.86 | 2019-2023 | Austedo Xr |
| Neurelis, INC. | $285.25 | 2023-2024 | Valtoco |
| Amgen INC. | $266.20 | 2019-2024 | Uplizna |
| Vanda Pharmaceuticals INC. | $244.86 | 2024-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $236.64 | 2019-2021 | |
| Octapharma USA, INC. | $226.41 | 2023-2025 | Balfaxar, Panzyga, Fibryga |
| Astrazeneca Pharmaceuticals LP | $200.75 | 2019-2024 | Andexxa |
| Otsuka America Pharmaceutical, INC. | $155.30 | 2023-2025 | Rexulti, Nuedexta |
| Sunovion Pharmaceuticals INC. | $125.00 | 2020 | |
| Argenx US, INC. | $122.40 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $119.79 | 2023 | Lybalvi |
| Janssen Pharmaceuticals, INC | $97.93 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $85.61 | 2025 | Ultomiris |
| Eisai INC. | $80.40 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $76.32 | 2019-2024 | Ingrezza |
| Janssen Biotech, INC. | $42.45 | 2025 | |
| Celgene Corporation | $40.52 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $39.56 | 2023 | Amvuttra, Onpattro |
| Grifols USA, LLC | $38.24 | 2023-2024 | Gamunex-C |
| Ceribell, INC. | $33.78 | 2025 | Pocket Eeg Device |
| Allergan, INC. | $33.68 | 2020 | |
| Invivyd INC | $30.09 | 2025 | Pemgarda |
| Amneal Pharmaceuticals LLC | $21.31 | 2023 | Rytary |
| Biogen, INC. | $17.93 | 2021 | |
| Medtronic USA, INC. | $16.31 | 2020 | |
| Lilly USA, LLC | $14.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Artem Sunik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.